Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582828 | 0.87 | — | — | |
| SCHEMBL7596995 | 0.85 | ADORA1 (0.36) | BRD4 | |
| SCHEMBL15024040 | 0.84 | — | — | |
| SCHEMBL441412 | 0.83 | ADORA2A (0.35) | — | |
| SCHEMBL7596991 | 0.78 | ADORA1 (0.34) | BRD4 | |
| SCHEMBL2028468 | 0.77 | ADORA2B (0.38) | — | |
| SCHEMBL12537250 | 0.77 | — | — | |
| SCHEMBL343674 | 0.75 | POLB (0.45) | — | |
| SCHEMBL8860729 | 0.74 | POLB (0.30) | — | |
| SCHEMBL15786367 | 0.74 | TYMP (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795580-B2 | Molecules for verifying oligonucleotide directed combinatorial synthesis and methods of making and using the same | HAYSTACK SCIENCES CORPORATION (US) | 2023-10-24 | — | — | US | disclosed |
| EP-2952587-B1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-20220154179-A1 | OLIGONUCLEOTIDE DIRECTED AND RECORDED COMBINITORIAL SYNTHESIS OF ENCODED PROBE MOLECULES | HAYSTACK SCIENCES CORPORATION (US) | 2022-05-19 | — | — | US | disclosed |
| US-20220145362-A1 | METHODS AND SYSTEMS FOR PROCESSING OR ANALYZING OLIGONUCLEOTIDE ENCODED MOLECULES | HAYSTACK SCIENCES CORPORATION (US) | 2022-05-12 | — | — | US | disclosed |
| US-11186836-B2 | Oligonucleotide directed and recorded combinatorial synthesis of encoded probe molecules | HAYSTACK SCIENCES CORPORATION (US) | 2021-11-30 | — | — | US | disclosed |
| US-20200332441-A1 | MOLECULES FOR VERIFYING OLIGONUCLEOTIDE DIRECTED COMBINATORIAL SYNTHESIS AND METHODS OF MAKING AND USING THE SAME | INSITRO, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200263163-A1 | MULTINOMIAL ENCODING FOR OLIGONUCLEOTIDE-DIRECTED COMBINATORIAL CHEMISTRY | HAYSTACK SCIENCES CORPORATION (US) | 2020-08-20 | — | — | US | disclosed |
| US-20190169607-A1 | OLIGONUCLEOTIDE DIRECTED AND RECORDED COMBINATORIAL SYNTHESIS OF ENCODED PROBE MOLECULES | INSITRO, INC. | 2019-06-06 | — | — | US | disclosed |
| US-20180334729-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2018-11-22 | — | — | US | disclosed |
| US-9920386-B2 | High throughput nucleic acid sequencing by expansion | STRATOS GENOMICS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20160208344-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2016-07-21 | — | — | US | disclosed |
| EP-2952587-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Stratos Genomics Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| EP-2171088-B1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS INC (US) | 2015-10-14 | — | — | EP | disclosed |
| US-20130158243-A1 | PROCESS FOR CONJUGATION OF NHS ESTERS WITH OLIGONUCLEOTIDES | SIGMA-ALDRICH CO. LLC (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2171088-A2 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Stratos Genomics Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008157696-A2 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158243-A1 | PROCESS FOR CONJUGATION OF NHS ESTERS WITH OLIGONUCLEOTIDES | LIG4, NCL, NUDT21 | BRD4 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.